Immune-inflamed cancers can be responsive to immunotherapies; however, their granular characterization is challenging. iBRIDGE integrates and ‘bridges’ bulk and scRNA-seq datasets and can be used to identify cell-type specific markers… Click to show full abstract
Immune-inflamed cancers can be responsive to immunotherapies; however, their granular characterization is challenging. iBRIDGE integrates and ‘bridges’ bulk and scRNA-seq datasets and can be used to identify cell-type specific markers of immune-inflamed tumors in multiple tumor cohorts.
               
Click one of the above tabs to view related content.